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Aims Inhibition of neprilysin, an enzyme degrading natriuretic and other vasoactive peptides, is beneficial in heart failure with
reduced ejection fraction (HFrEF), as shown in PARADIGM-HF which compared the angiotensin receptor–neprilysin
inhibitor (ARNI) sacubitril/valsartan with enalapril. As neprilysin is also one of many enzymes clearing amyloid-𝛽
peptides from the brain, there is a theoretical concern about the long-term effects of sacubitril/valsartan on cognition.
Therefore, we have examined dementia-related adverse effects (AEs) in PARADIGM-HF and placed these findings in
the context of other recently conducted HFrEF trials.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Methods
and results
In PARADIGM-HF, patients with symptomatic HFrEF were randomized to sacubitril/valsartan 97/103mg b.i.d. or
enalapril 10mg b.i.d. in a 1:1 ratio. We systematically searched AE reports, coded using the Medical Dictionary for
Regulatory Activities (MedDRA), using Standardized MedDRA Queries (SMQs) with ‘broad’ and ‘narrow’ preferred
terms related to dementia. In PARADIGM-HF, 8399 patients aged 18–96 years were randomized and followed for
a median of 2.25 years (up to 4.3 years). The narrow SMQ search identified 27 dementia-related AEs: 15 (0.36%)
on enalapril and 12 (0.29%) on sacubitril/valsartan [hazard ratio (HR) 0.73, 95% confidence interval (CI) 0.33–1.59].
The broad search identified 97 (2.30%) and 104 (2.48%) AEs (HR 1.01, 95% CI 0.75–1.37), respectively. The rates of
dementia-related AEs in both treatment groups in PARADIGM-HF were similar to those in three other recent trials
in HFrEF.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Conclusion We found no evidence that sacubitril/valsartan, compared with enalapril, increased dementia-related AEs, although
longer follow-up may be necessary to detect such a signal and more sensitive tools are needed to detect lesser
degrees of cognitive impairment. Further studies to address this question are warranted.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Introduction
The angiotensin receptor–neprilysin inhibitor sacubitril/valsartan
(formerly known as LCZ696) reduces the risk of both death and
hospitalization, compared with an ACE inhibitor, in patients with
heart failure and reduced ejection fraction (HFrEF).1,2 Decreased
breakdown of vasoactive peptides with favourable actions in heart
failure, including the natriuretic peptides, as a consequence of
neprilysin inhibition is believed to explain the additional benefit
of sacubitril/valsartan over renin–angiotensin blockade alone.3,4
Neprilysin, however, has other substrates including amyloid-𝛽
peptides in the central nervous system.5,6 Accumulation of certain
amyloid-𝛽 peptides is a pathognomonic feature of Alzheimer’s
type dementia.5,6 Although only one of many enzymatic and
non-enzymatic amyloid-𝛽 clearance pathways in the central ner-
vous system, concern has been raised that inhibition of neprilysin
could cause or accelerate amyloid-𝛽-related cognitive decline in
patients treated with sacubitril/valsartan.5–7 We have, therefore,
analysed relevant cognition- and memory-related adverse event
(AE) reports in the Prospective comparison of ARNi with ACEi to
Determine Impact on Global Mortailty and morbidity in Heart Fail-
ure (PARADIGM-HF) trial. 1,2 To place these findings in the context
of available evidence, we have analysed cognitive-related events in
three other trials in patients with HFrEF which recorded AEs in a
similar fashion.
Methods
PARADIGM-HF
The design and primary results of the PARADIGM-HF trial have been
previously described.4,8
Study patients and trial procedures
Patients had NYHA class II–IV symptoms, a LVEF ≤40% (changed to
≤35% by amendment), and a plasma BNP ≥150 pg/mL (or NT-proBNP
≥600 pg/mL). Patients with lower levels of natriuretic peptides (BNP
≥100 pg/mL, NT-proBNP ≥400 pg/mL) were eligible if they had been
hospitalized for heart failure within 12 months. Patients were required
to tolerate the equivalent of enalapril 10mg daily for at least 4 weeks
before screening, along with a stable dose of a beta-blocker (unless
contraindicated or not tolerated) and a mineralocorticoid receptor
antagonist (if indicated).
Cognition, memory, dementia-like and related events
In PARADIGM-HF, we systematically searched AE reports coded using
the 17.0 version of the Medical Dictionary for Regulatory Activities
(MedDRA) using Standardized MedDRA Queries (SMQs) with ‘broad’
and ‘narrow’ preferred terms (PTs) related to dementia-like AEs.3 The
precise terms used are detailed in Appendix 1.
The sponsor of PARADIGM-HF (Novartis) had two additional
chronic heart failure databases [the Valsartan Heart Failure Trial
(Val-HeFT) and the Aliskiren Trial to Minimize OutcomeS in Patients
with HEart failure trial (ATMOSPHERE)] in which the same searches
could be conducted and the other authors had an additional trial
[the Controlled Rosuvastatin Multinational Trial in Heart Failure
(CORONA)] the AEs from which could also searched in the same
fashion. ..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.. Val-HeFT
Val-HeFT was a randomized placebo-controlled trial which enrolled
5010 patients with clinical heart failure (NYHA class II–IV) and an
LVEF <40%.9 Study patients were randomly assigned to receive either
160mg of valsartan or placebo twice daily. The overall mean duration of
follow-up was 23 months (range, 0–38 months). The target dose was
achieved in 84% of patients receiving valsartan (mean dose, 254mg).
Dementia-related AEs were recorded as in PARADIGM-HF, using
standardized MedDRA queries with broad and narrow PTs, and we
analysed these in the same way as in PARADIGM-HF.
ATMOSPHERE
ATMOSPHERE enrolled 7016 participants with symptomatic heart fail-
ure (NYHA class II–IV), a LVEF ≤35%, and a plasma BNP concen-
tration of ≥150 pg/mL (or a NT-proBNP concentration ≥600 pg/mL)
or, if they had been hospitalized for heart failure within the previous
12 months, a BNP concentration of ≥100 pg/mL (or a NT-proBNP
concentration of ≥400 pg/mL).10,11 The average age of participants
was 63 years. Patients entered an open-label run-in period similar
to that in PARADIGM-HF with an initial period of treatment with
enalapril followed by treatment with the combination of enalapril and
aliskiren. Patients completing both treatment periods were randomized
to enalapril 5–10mg twice daily, aliskiren 150–300mg once daily, or
the combination of both drugs. The median follow-up was 36.6months.
Dementia-related AEs were again documented as described in the trials
above and analysed in the same way.
CORONA
CORONA enrolled 5011 participants aged at least 60 years with heart
failure (NYHA class II–IV) and a reduced LVEF (≤40% and ≤35%
if NYHA class II).12 The average age of participants was 73 years.
Patients were randomized to placebo or rosuvastatin 10mg daily. The
median follow-up was 32.8months. Dementia-related AEs were again
documented in the same way as in PARADIGM-HF, Val-HeFT, and
ATMOSPHERE, and analysed in the same way.
Results
PARADIGM-HF
Broad Standardized Medical Dictionary for Regulatory
Activities Queries
The broad SMQ PT analysis identified 104 cases in the sacu-
bitril/valsartan group (2.48%) and 97 (2.30%) in the enalapril
group. The most commonly reported dementia-related AEs in the
sacubitril/valsartan group (vs. the enalapril group) were PTs of ‘con-
fusional state’ (12 vs. 18), ‘somnolence’ (11 vs. 9), ‘delirium’ (10
vs. 8), and ‘amnesia/amnestic disorder’ (11 vs. 7) (Tables 1 and 2).
Narrow Standardized Medical Dictionary for Regulatory
Activities Queries
Using the narrow SMQ PTs, a total of 6 cases (0.14%) of unspecified
dementia were identified in the sacubitril/valsartan group and
10 cases (0.24%) in the enalapril group. The number of reports
of specific types of dementia in the sacubitril/valsartan group,
compared with the enalapril group were, respectively: Alzheimer’s
© 2016 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 1 Breakdown of cognition-related adverse events in trials analysed
PARADIGM-HF Val-HeFT CORONA ATMOSPHERE
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Enalapril
(n= 4212)
Sacub/val
(n= 4187)
Placebo
(n= 2494)
Valsartan
(n= 2506)
Placebo
(n= 2497)
Rosuvastatin
(n= 2514)
Enalapril
(n= 2336)
Aliskiren
(n= 2340)
Combination
(n= 2340)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Narrow SMQs
Dementia 10 6 4 5 11 14 13 11 11
Dementia Alzheimer’s type 2 2 0 1 4 6 1 5 4
Senile dementia 2 0 0 0 1 4 0 0 2
Vascular dementia 1 2 1 0 3 4 3 4 0
Pre-senile dementia 0 1 0 0 0 0 0 0 0
Hippocampal sclerosis 0 1 0 0 0 0 0 0 0
Frontotemporal dementia 0 0 0 1 0 0 0 0 0
Broad SMQs
Confusional state 18 12 31 20 21 19 11 13 17
Somnolence 9 11 17 13 6 5 5 4 4
Delirium 8 10 0 0 7 10 5 11 6
Amnesia/amnestic disorder 7 11 10 12 11 4 1 3 2
Memory impairment 6 6 17 9 9 22 2 9 4
Cognitive disorder 5 4 1 1 3 8 1 4 9
Hallucination/delusion/illusion 5 3 3 5 10 2 1 4 6
Aphasia 4 5 7 5 1 4 1 3 4
Disorientation 4 5 18 5 3 1 6 3 1
Agitation 3 7 14 12 2 4 2 5 5
Restlessness 2 3 13 8 6 3 1 7 4
Mental status changes 1 5 8 9 0 0 1 0 2
Affect lability 1 0 0 4 1 2 0 1 0
Feeling abnormal 1 0 1 4 3 1 1 2 2
Psychotic disorder 2 1 3 0 1 1 0 3 2
Mental impairment 2 0 3 0 1 1 0 0 0
Othera 4 9 9 11 11 5 5 5 10
SMQ, Standardized Medical Dictionary for Regulatory Activities query.
aFifteen additional terms (mental disorder, mood altered, mood swings, cerebral atrophy, speech disorder, initial insomnia, abnormal behaviour, aggression, apathy, apraxia,
somnambulism, inappropriate affect, personality change, disturbance in social behaviour, abulia); see Supplementary material online, Table S1 for breakdown by treatment
group.
type dementia (2 vs. 2), senile dementia (0 vs. 2), vascular dementia
(2 vs. 1), hippocampal sclerosis (1 vs. 0), and pre-senile dementia
(1 vs. 0) (Tables 1 and 2).
Annual rates of dementia-related adverse events
The crude annual rates of dementia-related AEs using both broad
and narrow SMQ PTs are shown in Table 2. These did not differ
significantly between sacubitril/valsartan and enalapril. Using the
broad SMQ PTs, the age-adjusted annual rate of these AEs was 0.95
[95% confidence interval (CI) 0.75–1.15] per 100 patient-years in
the sacubitril/valsartan group and 0.98 (95% CI 0.77–1.19) per 100
patient-years in the enalapril group.
Val-HeFT
Broad Standardized Medical Dictionary for Regulatory
Activities Queries
Total dementia-related AEs were reported in 139 (5.57%) of the
2494 patients receiving placebo compared with 102 (4.07%) of the .
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. 2506 study patients receiving valsartan. Of the broad SMQ terms,
confusional state was most commonly reported in the placebo
group (31 in the placebo group vs. 20 in the valsartan group)
followed by disorientation (18 vs. 5), memory impairment (17 vs.
9), and somnolence (17 vs. 13) (Tables 1 and 2).
Narrow Standardized Medical Dictionary for Regulatory
Activities Queries
Of the reported narrow SMQ terms, ‘unspecified dementia’ was
the most commonly reported type in the placebo group (4 vs. 5 in
the valsartan group). There was one case of vascular dementia in
the placebo group and none in the valsartan group and two other
reports of specific dementias in the valsartan group and none in
the placebo group (Tables 1 and 2).
Annual rates of dementia-related adverse events
The crude annual rates of dementia-related AEs using both broad
and narrow SMQ PTs are shown in Table 2. The rate of broad SMQ
reports was lower in the valsartan than in the placebo group. Using
© 2016 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 2 Number and rate of cognition-related adverse
events in trials analysed
Broad
SMQ n (ratea)
Narrow
SMQ n (ratea)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
PARADIGM-HF
Enalapril (n= 4212) 97 (0.91, 0.73–1.12) 15 (0.16, 0.10–0.27)
Sacubitril/valsartan
(n= 4187)
104 (0.92, 0.75–1.14) 12 (0.12, 0.07–0.21)
Hazard ratio (95% CI) 1.01 (0.75–1.37) 0.73 (0.33–1.59)
Val-HeFT
Placebo (n= 2494) 139 (3.03, 2.57–3.56) 5 (0.11, 0.04–0.26)
Valsartan (n= 2506) 102 (2.20, 1.82–2.67) 6 (0.13, 0.06–0.28)
Hazard ratio (95% CI) 0.73 (0.56–0.94) 1.12 (0.37–3.93)
CORONA
Placebo (n= 2497) 115 (1.62, 1.33–1.97) 19 (0.31, 0.20–0.48)
Rosuvastatin (n= 2514) 120 (1.74, 1.44–2.10) 28 (0.45, 0.31–0.65)
Hazard ratio (95% CI) 1.07 (0.82–1.41) 1.46 (0.82–2.62)
ATMOSPHERE
Enalapril (n= 2336) 52 (0.65, 0.48–0.85) 17 (0.21, 0.12–0.33)
Aliskiren (n= 2340) 81 (1.01,0.81–1.26) 20 (0.25, 0.15–0.38)
Combination
(n= 2340)
85 (1.05, 0.84–1.30) 16 (0.20, 0.11–0.32)
Hazard ratio (95% CI)b 1.57 (1.11–2.22) 1.18 (0.62–2.26)
Hazard ratio (95% CI)c 1.63 (1.15–2.30) 0.93 (0.47–1.85)
CI, confidence interval; SMQ, Standardized Medical Dictionary for Regulatory Activities
Query.
aRates were calculated per 100 patient-years (crude rate with 95% confidence interval). Rate
for broad SMQ includes narrow SMQ terms.
bAliskiren vs. enalapril.
cCombination vs. enalapril.
the broad SMQs, the age-adjusted annual rate of dementia-related
AEs was 2.43 (95% 1.94–2.92) per 100 patient-years in the placebo
group and 3.46 (95% CI 2.87–4.04) per 100 patient-years in the
valsartan group.
ATMOSPHERE
Broad Standardized Medical Dictionary for Regulatory
Activities Queries
The broad SMQ PT analysis of ATMOSPHERE identified 52 cases
(2.23%) in the enalapril group, 81 cases (3.46%) in the aliskiren
group, and 85 cases (3.63%) in the combination therapy group
(Tables 1 and 2). As in the other trials, the most commonly
reported PT in the enalapril group was confusional state (11
enalapril vs. 13 aliskiren vs. 17 combination) with delirium (5 vs.
11vs. 6) and memory impairment (2 vs. 9 vs. 4) the other most
common terms (Table 1).
Narrow Standardized Medical Dictionary for Regulatory
Activities Queries
A total of 13 cases (0.56%) of unspecified dementia were identified
in the enalapril group, 11 cases (0.47%) in the aliskiren group,
and 11 cases (0.47%) in the combination therapy group, with an
additional 4 cases of specific dementias in the enalapril group,
9 cases in the aliskiren group, and 6 cases in the combination
treatment group, giving totals of 17, 20, and 16 cases, respectively
(Tables 1 and 2). ..
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.. Annual rates of dementia-related adverse events
The crude annual rates of dementia-related AEs using both broad
and narrow SMQ PTs are shown in Table 2. The rate of broad
SMQ reports was lower in the enalapril group than in the aliskiren
and combination therapy groups. Using the broad SMQs, the
age-adjusted annual rate of dementia-related AEs was 0.71 (95%
CI 0.52–0.91) per 100 patient-years in the enalapril group, 1.14
(95% 0.89–1.39) per 100 patient-years in the aliskiren group, and
1.17 (95% CI 0.92–1.42) per 100 patient-years in the combination
therapy group.
CORONA
Broad Standardized Medical Dictionary for Regulatory
Activities Queries
The broad SMQ PT analysis of CORONA identified 115 cases
(4.61%) in the placebo group and 120 cases (4.77%) in the rosu-
vastatin group (Tables 1 and 2). As in the other trials, the most
commonly reported PT in the placebo group was confusional state
(21 placebo vs. 19 rosuvastatin), with amnesia/amnestic disorder
(11 vs. 4) the next most common term (Tables 1 and 2).
Narrow Standardized Medical Dictionary for Regulatory
Activities Queries
A total of 11 cases (0.44%) of unspecified dementia were identified
in the placebo group and 14 cases (0.56%) in the rosuvastatin
group, with an additional 8 cases (0.32%) of specific dementias in
the placebo group and 14 cases (0.56%) in the rosuvastatin group,
giving totals of 19 and 28 cases, respectively (Tables 1 and 2).
Annual rates of dementia-related adverse events
The crude annual rates of dementia-related AEs using both broad
and narrow SMQ PTs are shown in Table 2. These did not differ
significantly between placebo and rosuvastatin. Using the broad
SMQs, the age-adjusted annual rate of dementia-related AEs was
1.03 (95% CI 0.8–1.24) per 100 patient-years in the placebo
group and 1.06 (95% CI 0.86–1.27) per 100 patient-years in the
rosuvastatin group.
Baseline characteristics associated
with dementia-related adverse events
Because of their almost identical design, PARADIGM-HF and
ATMOSPHERE were pooled in order to examine which base-
line characteristics were associated with dementia-related AEs
(Table 3). As can be seen, patients with dementia-related AEs were
older, especially those with narrow SMQ PTs, and were more
likely to have AF, coronary heart disease, chronic lung disease,
and to have experienced a stroke than those without. Patients
with dementia-related AEs had a higher NT-proBNP and lower
estimated glomerular filtration rate (eGFR). These patients also
reported greater alcohol intake.
© 2016 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 3 Baseline characteristics of those with no dementia SMQ, those with the narrow SMQs, and those with the
broad SMQs in PARADIGM-HF and ATMOSPHERE combined
No dementia
(n= 15 028)
With dementia P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Narrow SMQs
(n= 80)
Broad SMQs
(n= 307)
Narrow
vs. none
Broad
vs. none
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age, years 63.4±11.6 75.4± 7.2 68.4±10.5 <0.001 <0.001
Male sex, n (%) 11748 (78.2) 58 (72.5) 252 (82.1) 0.221 0.100
Race, n (%) 0.002 <0.001
White 9818 (65.6) 68 (86.1) 250 (82.0)
Black 526 (3.5) 1 (1.3) 10 (3.3)
Asian 3238 (21.6) 8 (10.1) 27 (8.9)
Other 1395 (9.3) 2 (2.5) 18 (5.9)
Region, n (%) <0.001 <0.001
North America 722 (4.8) 5 (6.3) 52 (16.9)
Latin America 2512 (16.7) 3 (3.8) 37 (12.1)
Western Europe 3725 (24.8) 39 (48.8) 138 (45.0)
Central Europe 4700 (31.3) 25 (31.3) 45 (14.7)
Asia or Pacific region 3369 (22.4) 8 (10.0) 35 (11.4)
BMI, kg/m2 27.8± 5.4 27.2± 4.8 28.4± 6.1 0.296 0.041
Blood pressure, mmHg
Systolic 122.4±16.7 128.0± 16.9 122.6±18.0 0.003 0.789
Diastolic 75.3±10.7 75.6±10.5 72.9±10.9 0.798 <0.001
Heart rate, b.p.m. 72.1±12.3 71.8±12.7 70.5±11.8 0.823 0.026
Left ventricular ejection fraction, % 29.0± 6.0 30.4± 6.3 28.7± 6.4 0.042 0.322
NYHA class, n (%) 0.321 0.609
I 554 (3.7) 1 (1.3) 7 (2.3)
II 10 489 (69.9) 53 (66.3) 217 (70.7)
III 3855 (25.7) 26 (32.5) 80 (26.1)
IV 117 (0.8) 0 (0.0) 3 (1.0)
Ischaemic aetiology, n (%) 8723 (58.0) 55 (68.8) 188 (61.2) 0.053 0.262
HF duration, n (%) 0.522 <0.001
≤1 year 4799 (31.9) 21 (26.3) 64 (20.8)
>1 year and ≤5 years 5678 (37.8) 34 (42.5) 113 (36.8)
>5 years 4547 (30.3) 25 (31.3) 130 (42.3)
Smoking habit, n (%) 0.255 <0.001
Never smoked 7955 (52.9) 47 (58.8) 119 (38.8)
Ex-smoker 5018 (33.4) 27 (33.8) 140 (45.6)
Current smoker 2055 (13.7) 6 (7.5) 48 (15.6)
Alcohol habita, n (%) <0.001 0.010
<1 drink per day 13 226 (88.0) 59 (73.8) 257 (83.7)
1–2 drinks per day 1467 (9.8) 18 (22.5) 36 (11.7)
≥3 drinks per day 333 (2.2) 3 (3.8) 14 (4.6)
Medical history, n (%)
Previous HF hospitalization 9224 (61.4) 42 (52.5) 196 (63.8) 0.104 0.380
Myocardial infarction 6283 (41.8) 38 (47.5) 160 (52.1) 0.303 <0.001
Angina 3908 (26.0) 23 (28.7) 92 (30.0) 0.577 0.118
Stable angina 3031 (20.2) 18 (22.5) 58 (18.9) 0.604 0.581
Unstable angina 1655 (11.0) 7 (8.8) 59 (19.2) 0.519 <0.001
CABG 2190 (14.6) 17 (21.3) 74 (24.1) 0.092 <0.001
PCI 3085 (20.5) 20 (25.0) 75 (24.4) 0.324 0.094
Hypertension 9998 (66.5) 64 (80.0) 210 (68.4) 0.011 0.491
Diabetes 4719 (31.4) 13 (16.3) 119 (38.8) 0.004 0.006
Atrial fibrillation 5301 (35.3) 45 (56.3) 135 (44.0) <0.001 0.002
Stroke 1166 (7.8) 8 (10.0) 43 (14.0) 0.455 <0.001
Transient ischaemic attack 446 (3.0) 8 (10.0) 24 (7.8) <0.001 <0.001
Cancer 628 (4.2) 9 (11.3) 21 (6.8) 0.002 0.022
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Table 3 continued
No dementia
(n= 15 028)
With dementia P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Narrow SMQs
(n= 80)
Broad SMQs
(n= 307)
Narrow
vs. none
Broad
vs. none
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Asthma 504 (3.4) 5 (6.3) 18 (5.9) 0.152 0.016
COPD 1787 (11.9) 17 (21.3) 63 (20.5) 0.010 <0.001
Abdominal aortic aneurysm 190 (1.3) 2 (2.5) 6 (2.0) 0.325 0.287
Medication, n (%)
Digitalis 4687 (31.2) 21 (26.3) 73 (23.8) 0.342 0.006
Diuretic 12 026 (80.0) 64 (80.0) 246 (80.1) 0.996 0.963
ACE inhibitor/ARB before entry 12 781 (85.0) 60 (75.0) 248 (80.8) 0.012 0.038
Beta-blocker 13 886 (92.4) 69 (86.3) 288 (93.8) 0.039 0.355
Aldosterone antagonist 7128 (47.4) 23 (28.7) 122 (39.7) 0.001 0.008
Antiplatelet agent 8380 (55.8) 34 (42.5) 189 (61.6) 0.017 0.043
Aspirin 7747 (51.6) 29 (36.3) 174 (56.7) 0.006 0.075
Anticoagulant 4644 (30.9) 38 (47.5) 121 (39.4) 0.001 0.001
Lipid-lowering agent 8202 (54.6) 45 (56.3) 201 (65.5) 0.765 <0.001
Pacemaker 1718 (11.4) 14 (17.5) 68 (22.1) 0.089 <0.001
CRT 920 (6.1) 5 (6.3) 42 (13.7) 0.962 <0.001
ICD 2181 (14.5) 17 (21.3) 93 (30.3) 0.088 <0.001
12-lead ECG, n (%)
QRS duration 116.9± 35.1 112.2± 33.1 129.7± 47.1 0.237 <0.001
Atrial fibrillation 3538 (23.7) 29 (36.7) 70 (23.0) 0.007 0.769
Left bundle branch block 2987 (20.0) 12 (15.2) 83 (27.2) 0.288 0.002
Right bundle branch block 1114 (7.5) 2 (2.5) 22 (7.2) 0.096 0.874
Q waves 2636 (17.6) 15 (19.0) 49 (16.1) 0.754 0.476
Left ventricular hypertrophy 2706 (18.1) 10 (12.7) 39 (12.8) 0.210 0.017
Paced rhythm 1624 (10.9) 14 (17.7) 65 (21.3) 0.051 <0.001
Laboratory measures
eGFR, mL/min/1.73m2 70.7± 22.2 63.4±16.6 66.9± 21.9 0.004 0.003
eGFR <60mL/min/1.73m2, n (%) 4759 (31.7) 34 (42.5) 117 (38.2) 0.262 0.001
Serum creatinine, mg/dL 1.08± 0.29 1.12± 0.29 1.14± 0.32 0.038 0.017
NT-proBNP, pg/mLb 1410 (768–2770) 1595 (910–3003) 1679 (859–3201) 0.421 0.019
BMI, body mass index; CABG, coronary artery bypass graft; eGFR, estimated glomerular filtration rate; HF, heart failure; ICD, implantable cardioverter defibrillator; PCI,
percutaneous coronary intervention; SMQ, Standardized Medical Dictionary for Regulatory Activities Query.
aOne drink equals 12 fluid ounces of beer, 8 fluid ounces of malt liquor, 5 fluid ounces of wine, or 1.5 fluid ounces or a ‘shot’ of 80-proof distilled spirits or liquor (e.g. gin,
rum, vodka, or whiskey).
bNT-proBNP was reported as median and interquartile range.
Discussion
We examined the incidence of dementia-related AEs in
PARADIGM-HF because of a theoretical concern about the
potential effect of neprilysin inhibition on amyloid-𝛽 clearance
from the central nervous system. We have also carried out the
same analysis in three other trials, Val-HeFT, CORONA, and
ATMOSPHERE, which used a similar method to record AEs and
which were available to the authors. We are not aware of any
prior reports of this type.
We found, using the broadest collection of terms related to
dementia, that the annual rate of AEs was ∼1 per 100 patient-years
in PARADIGM-HF and ATMOSPHERE, and ∼70% higher in the
older patients enrolled in CORONA. The prevalence of cognitive .
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..
. impairment increases with age, and we found that patients with
dementia-related AEs were significantly older than patients with-
out these AEs. However, the age-adjusted rates were similar in
all three trials. For unknown reasons, the crude and age-adjusted
rates of these AEs were higher in Val-HeFT than in the three other
trials. This was not the case when the more specific SMQs were
examined, with rates of dementia-related AEs of ∼0.1–0.2 per 100
patient-years in each of PARADIGM-HF, Val-HeFT, and ATMO-
SPHERE (and a higher rate of 0.3–0.4 per 100 patient-years in
the older patients aged ≥60 years in CORONA). It is difficult to
place these findings in context because dementia-related AEs have
not been published in any clinical trial in heart failure. Examining
epidemiological data, the Framingham Heart Study, for its latest
epoch (2004–2008), reported an annual incidence of dementia
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of 0.44 (95% CI 0.36–0.56) per 100 person-years in individuals
with a mean age at entry of 72 years (range 60–101 years).13 In
the most recent report from the Cognitive Function and Ageing
Study (CFAS), the incidence of dementia in men in the UK aged
65–69 years was 0.50 (95% CI 0.25–1.02) per 100 person-years
and in men aged 70–74 years it was 0.87 (95% 0.51–1.51) per
100 person-years; in women, the corresponding rates were 0.46
(95% CI 0.22–0.96) and 0.64 (95% CI 0.33–1.23), respectively.14
The rates in these two epidemiological studies are not dissimilar
to those identified in CORONA which enrolled the oldest patients
among the trials we analysed. However, it is still likely that spon-
taneous AE reporting underestimated the true rate of dementia,
especially as it is thought that patients with heart failure have a
higher risk of cognitive dysfunction than healthy individuals.
We identified two studies reporting the incidence of dementia
in patients with heart failure. One used ICD-9 (International Clas-
sification of Diseases, 9th revision) codes to identify diagnoses of
both heart failure and dementia in a Medicare data set in the USA.
Over a median follow-up of 22 months, 1135 of 8062 patients
with heart failure (mean age 74.5 years; 53% women) developed
dementia. This equated to an incidence rate of ∼7.55 per 100
patient-years (ranging from ∼3.8 in those <65 years and 5.0 in
those aged 65–74 years to 26 per 100 patient-years in those
>85 years).15 A Swedish study used a similarly broad diagnosis of
heart failure. Using detailed clinical and cognitive testing at each
study follow-up visit, the investigators identified 205 subjects aged
83.3 years of age on average at baseline (80% were female). After a
mean follow-up of 5 years, the investigators reported an incidence
rate of dementia of 8.46 per 100 patient-years.16 It is very hard
to compare these studies with ours given the broad diagnosis of
heart failure, the much more advanced age of included subjects,
and quite different gender balance. Our trial patients were also
selected, with just the consenting process alone likely to exclude
patients with cognitive impairment. However, the broad SMQ AE
rate in CORONA and Val-HeFT was not far off the rate of incident
dementia among similarly aged patients in the US study.
In PARADIGM-HF, compared with enalapril, sacubitril/valsartan
did not lead to any increase in dementia-related AEs whether
defined using broad or narrow SMQs. Unpublished data from the
Omapatrilat Versus Enalapril Randomized Trial of Utility in Reduc-
ing Events (OVERTURE) study report show similar findings with
respect to omapatrilat (a neprilysin–ACE inhibitor) compared with
enalapril, although details of how this analysis was conducted are
not available.17 Specifically, 5 of 2886 patients (0.2%) treated with
omapatrilat had an AE related to memory impairment, compared
with 13 of 2884 (0.5%) patients treated with enalapril. The corre-
sponding figures of dementia were 1 (<0.1%) and 6 (0.2%). While
these findings provide some reassurance, the median duration of
follow-up in PARADIGM-HF was 2.7 years with a maximum of
4.3 years; the median follow-up in OVERTURE was only 1.2 years.
Detectable effects of a treatment on cognitive decline might take
much longer to occur, although this concern is less relevant in a
condition such as heart failure with limited life expectancy, com-
pared with conditions such as hypertension where treatment might
be given for decades. On the other hand, the concern about an
effect of neprilysin inhibition on amyloid-𝛽 peptides in the brain ..
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.. is theoretical and without any supporting experimental or clinical
evidence. Sacubitril/valsartan did not increase the concentration of
amyloidogenic species in the cerebrospinal fluid of healthy volun-
teers or brain tissue in cynomolgus monkeys.6,18 Moreover, human
genetic data do not provide consistent support for a relationship
between neprilysin and Alzheimer’s disease.19–21 Moreover, cogni-
tive decline in heart failure may not be wholly related to Alzheimer’s
type pathology and may also be associated with declining cardiac
function and vascular abnormalities. 22–24 In keeping with this, we
found that patients with dementia-related AEs had more evidence
of cardiovascular disease including coronary disease, stroke, and
AF, as well as a higher NT-proBNP level and lower eGFR. Effective
treatments that improve cardiac function might have a favourable
effect on cognition, and ARBs in particular have been postulated
to have such a benefit.22–24 Another related and important con-
tributor to cognitive decline in heart failure may be unplanned
admission to hospital with decompensation as episodes of criti-
cal illness are associated with marked cognitive decline over the
subsequent 12 months.25 It is plausible, therefore, that long-term
sacubitril/valsartan treatment, by improving cardiovascular function
and preventing hospitalization, may have a favourable effect on cog-
nitive function in patients with heart failure.
As mentioned above, the present analyses were limited as they
relied on AE reporting and not formal, systematic, cognitive func-
tion testing which is likely to be more sensitive in detecting
any effect of treatment. Serial assessment of cognitive function
using the Mini Mental State Examination is being conducted in
the Prospective comparison of ARni with Arb Global Outcomes
in heart failure with preserved ejectioN fraction (PARAGON-HF,
ClinicalTrials.gov, IDNCT01920711) trial which is comparing sacu-
bitril/valsartan with valsartan in ∼4300 patients with heart fail-
ure and preserved EF. In a new study, the Prospective Evaluation
of cognitive function in heart failure: A Randomized double-blind
Study in Patients with Preserved Ejection fraction Cardiac fail-
ure Treated wIth Valsartan or Entresto (PERSPECTIVE, ClinicalTri-
als.gov, ID NCT02884206), a battery of more sensitive cognitive
function tests will be utilized and the effects of sacubitril/valsartan
on amyloid-𝛽 within the brain will be examined using positron
emission tomography imaging. Patients with clinically obvious cog-
nitive decline were excluded from the trials analysed. Longer
term follow-up might identify effects not seen over the maximum
4.3 years of follow-up in PARADIGM-HF.
In summary, we found that the incidence of dementia-related
AEs in patients treated with sacubitril/valsartan was similar to
that in patients treated with enalapril in PARADIGM-HF and in
patients enrolled in other recent heart trials. Our findings do not
support the theoretical concerns about adverse cognitive effects
of sacubitril/valsartan which has been shown definitively to reduce
morbidity and mortality in patients with HFrEF.
Supplementary Information
Additional Supporting Information may be found in the online
version of this article:
Table S1. Additional broad SMQs.
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Appendix 1. Cognition, memory,
dementia-like and related events
In PARADIGM-HF, we systematically searched adverse event (AE)
reports coded using the 17.0 version of the Medical Dictionary
for Regulatory Activities (MedDRA) using Standardized MedDRA
Queries (SMQs) with ‘broad’ and ‘narrow’ preferred terms (PTs)
related to dementia-like AEs.3
The broad PTs used were: abnormal behaviour, abulia, activities
of daily living impaired, affect lability, aggression, agitation, agnosia,
amnesia, amnestic disorder, anterograde amnesia, apathy, aphasia,
apraxia, borderline mental impairment, cerebral atrophy, cerebral
atrophy congenital, change in sustained attention, cognitive dis-
order, confusional state, delirium, delusion, delusional disorder
(jealous type), delusional disorder (unspecified type), disinhibi-
tion, disorientation, disturbance in social behaviour, executive
dysfunction, feeling abnormal, flat affect, hallucination, hostility,
hypomania, illusion, impaired reasoning, inappropriate affect, initial
insomnia, intelligence test abnormal, irritability post-vaccinal,
judgement impaired, learning disability, learning disorder, memory
impairment, mental status changes, mood altered, mood swings,
morose, negativism, neuropsychological test abnormal, personal-
ity change, prodromal Alzheimer’s disease, psychotic behaviour,
psychotic disorder, restlessness, sexually inappropriate behaviour,
social avoidant behaviour, somnambulism, somnolence, sopor,
speech disorder, suspiciousness, symbolic dysfunction, thinking
abnormal, transient global amnesia, vascular cognitive impairment
and visual cortex atrophy.
The narrow PTs were: behavioural and psychiatric symptoms
of dementia, Creutzfeldt–Jakob disease, dementia, dementia
of Alzheimer’s type, dementia of Alzheimer’s type (uncompli-
cated), dementia of Alzheimer’s type (with delirium), dementia of
Alzheimer’s type (with delusions), dementia of Alzheimer’s type
(with depressed mood), dementia with Lewy bodies, frontotem-
poral dementia, hippocampal sclerosis, Korsakoff ’s syndrome, Mini
Mental State Examination abnormal, pre-senile dementia, progres-
sive supranuclear palsy, senile dementia, variant Creutzfeldt–Jakob
disease, and vascular dementia.
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